ROS1 and neoplasm: suggested that ROS1 is highly expressed in E‐cadherin (CDH1)‐deficient breast cancer, and its inhibitors (such as GSK1363089 and crizotinib) can destroy tumor cells via a synergistic lethal pathway.27